Ascletis Pharma Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Millions HKD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 1, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	18,018	11,241	2,904	1,522	5,153	3,575
Market Cap Growth	140.11%	287.10%	90.74%	-70.46%	44.13%	13.38%
Enterprise Value	15,908	9,272	665	-1,197	2,236	435
Last Close Price	16.98	11.39	3.01	1.46	4.74	3.29
PS Ratio	7983.94	4980.84	2126.81	24.42	84.27	37.89
PB Ratio	8.37	5.22	1.39	0.59	1.80	1.07
P/TBV Ratio	8.42	5.25	1.40	0.60	1.81	1.10
EV/Sales Ratio	-	4108.47	486.91	-	36.57	4.61
Debt / Equity Ratio	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt / Equity Ratio	-0.98	-0.98	-0.99	-0.98	-0.98	-0.92
Net Debt / EBITDA Ratio	4.03	4.03	4.98	7.78	7.69	12.21
Net Debt / FCF Ratio	4.55	4.55	5.66	9.98	11.84	16.46
Asset Turnover	0.00	0.00	0.00	0.02	0.02	0.03
Inventory Turnover	0.48	0.48	0.11	2.30	2.05	0.66
Quick Ratio	14.90	14.90	12.82	16.50	23.24	28.26
Current Ratio	15.05	15.05	12.88	16.58	23.52	28.93
Return on Equity (ROE)	-18.45%	-18.45%	-13.97%	-5.93%	-11.95%	-6.97%
Return on Assets (ROA)	-14.45%	-14.45%	-10.96%	-7.50%	-7.94%	-4.88%
Return on Capital Employed (ROCE)	-25.00%	-25.00%	-20.50%	-13.10%	-13.70%	-8.40%
Earnings Yield	-2.22%	-3.56%	-11.03%	-10.47%	-6.91%	-6.83%
FCF Yield	-	-4.13%	-12.60%	-16.64%	-4.60%	-5.21%
Buyback Yield / Dilution	2.92%	2.92%	6.75%	1.19%	0.96%	-5.53%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.